Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC (Seraph) in neoadjuvant HER2-positive breast cancer
NCT05134519Phase 2Unknown
- Sponsor
- Xijing Hospital
- Start
- Nov 2021
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in HER2-positive breast cancer, sponsored by Xijing Hospital. Primary endpoint: Pathological Complete Response Rate. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05134519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134519.